{ "run": { "id": "cmnr1361y0306p658dj7en2pn", "region": "US", "assetId": "cmnr1360q0300p658wb4hjs7z", "ticker": "CRL", "snapshotId": "cmnr1361f0304p6583p8284oh", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:18.020Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr1361f0304p6583p8284oh", "assetId": "cmnr1360q0300p658wb4hjs7z", "asOf": "2026-04-08T20:00:03.000Z", "snapshot": { "asOf": "2026-04-08T20:00:03.000Z", "quote": { "asOf": "2026-04-08T20:00:03.000Z", "open": null, "price": 175.07, "dayLow": 173.94, "volume": 745603, "dayHigh": 180.79, "currency": "USD", "prevClose": 169.54, "week52Low": 91.86, "week52High": 228.88 }, "fundamentals": { "pe": -69.9862542955326, "beta": 1.25458328447134, "epsTTM": -2.91, "fcfTTM": 283129000, "growth": { "epsYoy": -15.55, "revenueYoy": -0.008544961480142292 }, "sector": "Services-Commercial Physical & Biological Research", "margins": { "net": 0.1245938261923238, "gross": 0.1025905860360001, "operating": 0.1479955252052629 }, "website": "http://criver.com", "industry": "Pharmaceuticals", "pegRatio": 0.0450072374890885, "ebitdaTTM": 485647000, "forwardPe": 19.2313503305005, "marketCap": 7322905711, "totalCash": 213770000, "totalDebt": 2136526000, "debtEquity": 0.675126634077285, "quickRatio": 0.8235415932126232, "revenueTTM": 2923933000, "companyName": "CHARLES RIVER LABORATORIES INTERNATIONAL, INC.", "priceToBook": 3.14344266961137, "currentRatio": 1.29164476062536, "dividendYield": null, "returnOnAssets": 0.05105570490434903, "returnOnEquity": -0.0456097553268471, "analystOpinions": null, "businessSummary": "Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.", "enterpriseValue": 12016960240, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 19700, "sharesOutstanding": 49227800, "enterpriseToEbitda": 24.74422829750827, "analystTargetMedian": null, "enterpriseToRevenue": 4.109861696557342, "operatingCashflowTTM": 737646000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:18.003Z" }, "results": [ { "id": "cmnr136210308p658re40w8sp", "runId": "cmnr1361y0306p658dj7en2pn", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"CRL\",\"currency\":\"USD\",\"current_price\":175.07,\"target_price_6m\":180,\"target_price_12m\":185,\"recommendation\":\"HOLD\",\"confidence\":0.50,\"thesis_bullets\":[\"Negative TTM EPS reflects goodwill impairments masking underlying profitability\",\"Forward PE ~19x implies meaningful earnings recovery already priced in\",\"Revenue essentially flat YoY with weak biotech end-market spending\",\"FCF generation of ~$283M supports debt servicing but limits flexibility\",\"Valuation near fair value on normalized earnings with limited margin of safety\"],\"key_drivers\":[{\"driver\":\"Biotech funding environment and R&D outsourcing demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Goodwill impairment charges depressing reported earnings\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated leverage with $2.1B total debt vs $214M cash\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Operating cash flow of $738M supporting deleveraging\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cost restructuring and headcount optimization efforts\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Flat revenue growth limits multiple expansion potential\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Potential pharma M&A activity boosting CRO demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"GLP-1 and oncology pipeline growth driving preclinical volumes\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Sustained weakness in small/mid-cap biotech funding reduces order flow\",\"Further goodwill or intangible impairments if segments underperform\",\"Interest expense burden increases if rates stay higher for longer\",\"Regulatory or pricing pressure on preclinical safety assessment services\",\"Key client concentration risk if large pharma consolidates or insources\"],\"assumptions\":{\"revenue_cagr_3y\":0.035,\"ebit_margin_target\":0.16,\"wacc\":0.095,\"terminal_multiple\":17},\"scenarios\":{\"bear\":{\"target_price\":140,\"prob\":0.25,\"notes\":\"Continued biotech funding drought, margin compression, further impairments push multiple to ~15x normalized earnings.\"},\"base\":{\"target_price\":185,\"prob\":0.50,\"notes\":\"Gradual revenue recovery to low-single-digit growth, margins normalize near 16%, ~20x forward earnings.\"},\"bull\":{\"target_price\":225,\"prob\":0.25,\"notes\":\"Biotech funding rebound drives mid-single-digit organic growth, margin expansion to 18%, multiple re-rates to ~22x.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA approach on normalized earnings. Forward EPS ~$9.10 implied from forward PE. 12M target assumes modest earnings growth with stable multiple. Negative TTM EPS driven by non-cash impairments; underlying FCF positive. Mixed evidence (flat revenue, high debt, but decent cash generation) supports HOLD. Probability-weighted scenario value ~$183, consistent with base target. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "ai-equity-research-v1", "risks": [ "Sustained weakness in small/mid-cap biotech funding reduces order flow", "Further goodwill or intangible impairments if segments underperform", "Interest expense burden increases if rates stay higher for longer", "Regulatory or pricing pressure on preclinical safety assessment services", "Key client concentration risk if large pharma consolidates or insources" ], "ticker": "CRL", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual revenue recovery to low-single-digit growth, margins normalize near 16%, ~20x forward earnings.", "target_price": 185 }, "bear": { "prob": 0.25, "notes": "Continued biotech funding drought, margin compression, further impairments push multiple to ~15x normalized earnings.", "target_price": 140 }, "bull": { "prob": 0.25, "notes": "Biotech funding rebound drives mid-single-digit organic growth, margin expansion to 18%, multiple re-rates to ~22x.", "target_price": 225 } }, "confidence": 0.5, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.035, "terminal_multiple": 17, "ebit_margin_target": 0.16 }, "key_drivers": [ { "driver": "Biotech funding environment and R&D outsourcing demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Goodwill impairment charges depressing reported earnings", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated leverage with $2.1B total debt vs $214M cash", "impact": "MED", "direction": "NEG" }, { "driver": "Operating cash flow of $738M supporting deleveraging", "impact": "MED", "direction": "POS" }, { "driver": "Cost restructuring and headcount optimization efforts", "impact": "MED", "direction": "POS" }, { "driver": "Flat revenue growth limits multiple expansion potential", "impact": "HIGH", "direction": "NEG" }, { "driver": "Potential pharma M&A activity boosting CRO demand", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1 and oncology pipeline growth driving preclinical volumes", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended forward PE and EV/EBITDA approach on normalized earnings. Forward EPS ~$9.10 implied from forward PE. 12M target assumes modest earnings growth with stable multiple. Negative TTM EPS driven by non-cash impairments; underlying FCF positive. Mixed evidence (flat revenue, high debt, but decent cash generation) supports HOLD. Probability-weighted scenario value ~$183, consistent with base target. Not investment advice.", "current_price": 175.07, "recommendation": "HOLD", "thesis_bullets": [ "Negative TTM EPS reflects goodwill impairments masking underlying profitability", "Forward PE ~19x implies meaningful earnings recovery already priced in", "Revenue essentially flat YoY with weak biotech end-market spending", "FCF generation of ~$283M supports debt servicing but limits flexibility", "Valuation near fair value on normalized earnings with limited margin of safety" ], "target_price_6m": 180, "target_price_12m": 185 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 49968, "createdAt": "2026-04-09T05:20:18.020Z", "usage": { "inputTokens": 3606, "outputTokens": 2109, "costUsd": 0.070755 } }, { "id": "cmnr13621030bp6584llquq9m", "runId": "cmnr1361y0306p658dj7en2pn", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model v1.0\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"CRL\",\n \"currency\": \"USD\",\n \"current_price\": 175.07,\n \"target_price_6m\": 180.0,\n \"target_price_12m\": 185.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"CRO market growth supports revenue stability.\",\n \"Recent EPS decline indicates short-term challenges.\",\n \"Strong free cash flow enhances financial flexibility.\",\n \"High valuation multiples reflect growth expectations.\",\n \"Mixed operational metrics warrant cautious approach.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"Outsourcing trend in pharma R&D\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Revenue growth recovery\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Operating margin expansion\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory environment changes\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Competitive pressure\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Debt levels and interest rates\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n {\"driver\": \"Geographic diversification\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n {\"driver\": \"Client contract renewals\", \"impact\": \"HIGH\", \"direction\": \"POS\"}\n ],\n \"risks\": [\n \"Economic slowdown affecting R&D budgets\",\n \"Regulatory delays in drug approvals\",\n \"Increased competition reducing pricing power\",\n \"Execution risks in margin improvement\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.095,\n \"terminal_multiple\": 20.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 160.0, \"prob\": 0.3, \"notes\": \"Slower growth and margin compression.\"},\n \"base\": {\"target_price\": 185.0, \"prob\": 0.5, \"notes\": \"Moderate recovery and stable margins.\"},\n \"bull\": {\"target_price\": 210.0, \"prob\": 0.2, \"notes\": \"Strong outsourcing adoption and cost savings.\"}\n },\n \"method_notes\": \"Valuation based on DCF with assumed 3% revenue CAGR and 15% EBIT margin. HOLD due to limited upside and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model v1.0", "risks": [ "Economic slowdown affecting R&D budgets", "Regulatory delays in drug approvals", "Increased competition reducing pricing power", "Execution risks in margin improvement" ], "ticker": "CRL", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate recovery and stable margins.", "target_price": 185 }, "bear": { "prob": 0.3, "notes": "Slower growth and margin compression.", "target_price": 160 }, "bull": { "prob": 0.2, "notes": "Strong outsourcing adoption and cost savings.", "target_price": 210 } }, "confidence": 0.6, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.03, "terminal_multiple": 20, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Outsourcing trend in pharma R&D", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth recovery", "impact": "MED", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory environment changes", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Debt levels and interest rates", "impact": "LOW", "direction": "NEG" }, { "driver": "Geographic diversification", "impact": "LOW", "direction": "POS" }, { "driver": "Client contract renewals", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Valuation based on DCF with assumed 3% revenue CAGR and 15% EBIT margin. HOLD due to limited upside and mixed evidence. Not investment advice.", "current_price": 175.07, "recommendation": "HOLD", "thesis_bullets": [ "CRO market growth supports revenue stability.", "Recent EPS decline indicates short-term challenges.", "Strong free cash flow enhances financial flexibility.", "High valuation multiples reflect growth expectations.", "Mixed operational metrics warrant cautious approach." ], "target_price_6m": 180, "target_price_12m": 185 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 332, "createdAt": "2026-04-09T05:20:18.020Z", "usage": { "inputTokens": 2116, "outputTokens": 3329, "costUsd": 0.001991 } }, { "id": "cmnr136210309p65899owaos5", "runId": "cmnr1361y0306p658dj7en2pn", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Base\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"CRL\",\n \"currency\": \"USD\",\n \"current_price\": 175.07,\n \"target_price_6m\": 177.00,\n \"target_price_12m\": 180.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Biotech funding environment remains constrained, limiting near-term preclinical research volume growth.\",\n \"Forward P/E of 19.2x prices in an earnings recovery that currently lacks near-term visibility.\",\n \"Strong market position in research models is offset by NHP supply chain vulnerabilities.\",\n \"Free cash flow generation remains solid at $283M, supporting debt service capabilities.\",\n \"Valuation appears fair at current levels, balancing recovery potential against macroeconomic headwinds.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biotech VC Funding Levels\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"NHP Supply Chain Stability\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Interest Rate Environment\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Large Pharma R&D Budgets\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt Servicing Costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Preclinical Study Cancellations\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged downturn in early-stage biotech funding.\",\n \"Regulatory scrutiny over animal testing and NHP imports.\",\n \"Increased competition from lower-cost overseas CROs.\",\n \"High leverage ratio limiting strategic M&A flexibility.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.16,\n \"wacc\": 0.085,\n \"terminal_multiple\": 14.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 140.00,\n \"prob\": 0.3,\n \"notes\": \"Biotech funding remains depressed, leading to revenue contraction and margin compression.\"\n },\n \"base\": {\n \"target_price\": 180.00,\n \"prob\": 0.5,\n \"notes\": \"Gradual recovery in R&D spending supports low single-digit growth and stable margins.\"\n },\n \"bull\": {\n \"target_price\": 215.00,\n \"prob\": 0.2,\n \"notes\": \"Surge in biotech VC funding drives robust preclinical demand and multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of 20x forward P/E and DCF (8.5% WACC, 14x terminal EV/EBITDA). The 12M target of $180 implies a ~2.8% upside, warranting a HOLD rating due to mixed biotech funding signals and supply chain risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "EquityResearch_Base", "risks": [ "Prolonged downturn in early-stage biotech funding.", "Regulatory scrutiny over animal testing and NHP imports.", "Increased competition from lower-cost overseas CROs.", "High leverage ratio limiting strategic M&A flexibility." ], "ticker": "CRL", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual recovery in R&D spending supports low single-digit growth and stable margins.", "target_price": 180 }, "bear": { "prob": 0.3, "notes": "Biotech funding remains depressed, leading to revenue contraction and margin compression.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Surge in biotech VC funding drives robust preclinical demand and multiple expansion.", "target_price": 215 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.03, "terminal_multiple": 14, "ebit_margin_target": 0.16 }, "key_drivers": [ { "driver": "Biotech VC Funding Levels", "impact": "HIGH", "direction": "POS" }, { "driver": "NHP Supply Chain Stability", "impact": "HIGH", "direction": "NEG" }, { "driver": "Interest Rate Environment", "impact": "MED", "direction": "POS" }, { "driver": "Large Pharma R&D Budgets", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt Servicing Costs", "impact": "MED", "direction": "NEG" }, { "driver": "Preclinical Study Cancellations", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation based on a blend of 20x forward P/E and DCF (8.5% WACC, 14x terminal EV/EBITDA). The 12M target of $180 implies a ~2.8% upside, warranting a HOLD rating due to mixed biotech funding signals and supply chain risks. Not investment advice.", "current_price": 175.07, "recommendation": "HOLD", "thesis_bullets": [ "Biotech funding environment remains constrained, limiting near-term preclinical research volume growth.", "Forward P/E of 19.2x prices in an earnings recovery that currently lacks near-term visibility.", "Strong market position in research models is offset by NHP supply chain vulnerabilities.", "Free cash flow generation remains solid at $283M, supporting debt service capabilities.", "Valuation appears fair at current levels, balancing recovery potential against macroeconomic headwinds." ], "target_price_6m": 177, "target_price_12m": 180 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 25403, "createdAt": "2026-04-09T05:20:18.020Z", "usage": { "inputTokens": 2453, "outputTokens": 856, "costUsd": 0.015178 } }, { "id": "cmnr136210307p658pbwgiyf7", "runId": "cmnr1361y0306p658dj7en2pn", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:03.000Z\",\"ticker\":\"CRL\",\"currency\":\"USD\",\"current_price\":175.07,\"target_price_6m\":181,\"target_price_12m\":184.5,\"recommendation\":\"HOLD\",\"confidence\":0.61,\"thesis_bullets\":[\"Biotech and discovery demand remains soft, capping near-term revenue growth.\",\"Cost actions and mix should lift margins from a depressed earnings base.\",\"Large pharma outsourcing supports medium-term preclinical demand resilience.\",\"Leverage limits flexibility despite positive operating cash flow generation.\",\"Valuation looks roughly fair for a gradual recovery, not a sharp rebound.\"],\"key_drivers\":[{\"driver\":\"Biotech funding recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Large pharma outsourcing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cost savings execution\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Research models normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt reduction pace\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China demand weakness\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory animal-use scrutiny\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"End-market destocking\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Biotech funding slump persists longer than expected.\",\"Regulatory scrutiny disrupts animal supply or customer demand.\",\"Restructuring savings and margin recovery undershoot.\",\"High debt magnifies downside in a weak volume environment.\",\"Data inconsistencies in snapshot fundamentals reduce model precision.\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.195,\"wacc\":0.095,\"terminal_multiple\":12.5},\"scenarios\":{\"bear\":{\"target_price\":145,\"prob\":0.25,\"notes\":\"Demand stays soft and margin recovery stalls.\"},\"base\":{\"target_price\":184.5,\"prob\":0.5,\"notes\":\"Orders improve gradually and savings support margins.\"},\"bull\":{\"target_price\":225,\"prob\":0.25,\"notes\":\"Biotech recovery and utilization rebound drive rerating.\"}},\"method_notes\":\"Blended normalized EV/EBITDA and FCF approach using snapshot fields as baseline. Snapshot quote was kept unchanged; some fundamentals appear internally inconsistent versus price/EPS, so assumptions carry more weight. 12M upside is ~5%, below BUY threshold, supporting HOLD. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "OpenAI o3", "risks": [ "Biotech funding slump persists longer than expected.", "Regulatory scrutiny disrupts animal supply or customer demand.", "Restructuring savings and margin recovery undershoot.", "High debt magnifies downside in a weak volume environment.", "Data inconsistencies in snapshot fundamentals reduce model precision." ], "ticker": "CRL", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Orders improve gradually and savings support margins.", "target_price": 184.5 }, "bear": { "prob": 0.25, "notes": "Demand stays soft and margin recovery stalls.", "target_price": 145 }, "bull": { "prob": 0.25, "notes": "Biotech recovery and utilization rebound drive rerating.", "target_price": 225 } }, "confidence": 0.61, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.055, "terminal_multiple": 12.5, "ebit_margin_target": 0.195 }, "key_drivers": [ { "driver": "Biotech funding recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Large pharma outsourcing", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost savings execution", "impact": "MED", "direction": "POS" }, { "driver": "Research models normalization", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction pace", "impact": "MED", "direction": "POS" }, { "driver": "China demand weakness", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory animal-use scrutiny", "impact": "HIGH", "direction": "NEG" }, { "driver": "End-market destocking", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended normalized EV/EBITDA and FCF approach using snapshot fields as baseline. Snapshot quote was kept unchanged; some fundamentals appear internally inconsistent versus price/EPS, so assumptions carry more weight. 12M upside is ~5%, below BUY threshold, supporting HOLD. not investment advice", "current_price": 175.07, "recommendation": "HOLD", "thesis_bullets": [ "Biotech and discovery demand remains soft, capping near-term revenue growth.", "Cost actions and mix should lift margins from a depressed earnings base.", "Large pharma outsourcing supports medium-term preclinical demand resilience.", "Leverage limits flexibility despite positive operating cash flow generation.", "Valuation looks roughly fair for a gradual recovery, not a sharp rebound." ], "target_price_6m": 181, "target_price_12m": 184.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_07e33af81cf11c230069d757a5e50c8194a401b161e91f75b8", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 59829, "createdAt": "2026-04-09T05:20:18.020Z", "usage": { "inputTokens": 2389, "outputTokens": 2861, "costUsd": 0.044235 } }, { "id": "cmnr13621030ap658x1l6oeuk", "runId": "cmnr1361y0306p658dj7en2pn", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:03.000Z\",\n \"ticker\": \"CRL\",\n \"currency\": \"USD\",\n \"current_price\": 175.07,\n \"target_price_6m\": 192,\n \"target_price_12m\": 205,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Leading CRO with strong preclinical expertise\",\n \"Biotech funding recovery to lift demand\",\n \"Forward P/E of 19x appears attractive\",\n \"High debt load adds financial risk\",\n \"Secular trend in outsourced R&D\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"R&D outsourcing by pharma\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Biotech client spending rebound\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Preclinical margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"High leverage and interest costs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition from rival CROs\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory tailwinds for approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macro sensitivity of funding\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"New therapy pipeline demand\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged biotech budget cuts\",\n \"Rising interest expense pressure\",\n \"Key client contract losses\",\n \"Acquisition integration issues\",\n \"Adverse regulatory shifts\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.16,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 140,\n \"prob\": 0.3,\n \"notes\": \"Persistent weak demand erodes margins.\"\n },\n \"base\": {\n \"target_price\": 205,\n \"prob\": 0.5,\n \"notes\": \"Gradual recovery matches forward earnings.\"\n },\n \"bull\": {\n \"target_price\": 255,\n \"prob\": 0.2,\n \"notes\": \"Strong funding surge drives high growth.\"\n }\n },\n \"method_notes\": \"DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple. BUY reflects 17% 12M upside with balanced bull/bear factors. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:03.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged biotech budget cuts", "Rising interest expense pressure", "Key client contract losses", "Acquisition integration issues", "Adverse regulatory shifts" ], "ticker": "CRL", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual recovery matches forward earnings.", "target_price": 205 }, "bear": { "prob": 0.3, "notes": "Persistent weak demand erodes margins.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Strong funding surge drives high growth.", "target_price": 255 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.06, "terminal_multiple": 15, "ebit_margin_target": 0.16 }, "key_drivers": [ { "driver": "R&D outsourcing by pharma", "impact": "HIGH", "direction": "POS" }, { "driver": "Biotech client spending rebound", "impact": "HIGH", "direction": "POS" }, { "driver": "Preclinical margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "High leverage and interest costs", "impact": "MED", "direction": "NEG" }, { "driver": "Competition from rival CROs", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory tailwinds for approvals", "impact": "MED", "direction": "POS" }, { "driver": "Macro sensitivity of funding", "impact": "HIGH", "direction": "NEG" }, { "driver": "New therapy pipeline demand", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using revenue CAGR, target EBIT margin, WACC and terminal multiple. BUY reflects 17% 12M upside with balanced bull/bear factors. not investment advice.", "current_price": 175.07, "recommendation": "BUY", "thesis_bullets": [ "Leading CRO with strong preclinical expertise", "Biotech funding recovery to lift demand", "Forward P/E of 19x appears attractive", "High debt load adds financial risk", "Secular trend in outsourced R&D" ], "target_price_6m": 192, "target_price_12m": 205 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "41248a31-2fbe-9805-9005-f9508c9b929f", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 16506, "createdAt": "2026-04-09T05:20:18.020Z", "usage": { "inputTokens": 2727, "outputTokens": 3146, "costUsd": 0.055371 } } ] } }